Adamas Pharmaceuticals (NASDAQ:ADMS) – Equities researchers at William Blair reduced their Q1 2018 EPS estimates for shares of Adamas Pharmaceuticals in a research note issued on Monday, April 16th. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings of ($1.51) per share for the quarter, down from their previous forecast of ($1.50). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Adamas Pharmaceuticals’ FY2018 earnings at ($6.57) EPS.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.09). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.84 million. Adamas Pharmaceuticals’s revenue was up 1435.1% compared to the same quarter last year. During the same period last year, the company posted ($0.68) EPS.
Several other brokerages have also issued reports on ADMS. Mizuho reiterated a “buy” rating and set a $48.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, January 23rd. BidaskClub upgraded Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 25th. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a report on Wednesday, January 3rd. Finally, Piper Jaffray set a $52.00 target price on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 19th. Two analysts have rated the stock with a sell rating and twelve have given a buy rating to the stock. Adamas Pharmaceuticals has an average rating of “Buy” and an average target price of $42.89.
Shares of Adamas Pharmaceuticals stock opened at $25.01 on Wednesday. The stock has a market cap of $653.29, a PE ratio of -6.30 and a beta of 1.59. The company has a debt-to-equity ratio of 1.55, a current ratio of 10.79 and a quick ratio of 10.69. Adamas Pharmaceuticals has a 52-week low of $13.50 and a 52-week high of $44.00.
Several hedge funds have recently modified their holdings of ADMS. Deutsche Bank AG lifted its holdings in shares of Adamas Pharmaceuticals by 632.7% during the fourth quarter. Deutsche Bank AG now owns 506,369 shares of the specialty pharmaceutical company’s stock worth $17,159,000 after buying an additional 437,263 shares during the last quarter. Driehaus Capital Management LLC acquired a new position in shares of Adamas Pharmaceuticals during the fourth quarter worth approximately $7,356,000. UBS Asset Management Americas Inc. acquired a new position in shares of Adamas Pharmaceuticals during the fourth quarter worth approximately $6,680,000. Ardsley Advisory Partners acquired a new position in shares of Adamas Pharmaceuticals during the fourth quarter worth approximately $5,253,000. Finally, Macquarie Group Ltd. lifted its holdings in shares of Adamas Pharmaceuticals by 18.6% during the fourth quarter. Macquarie Group Ltd. now owns 890,962 shares of the specialty pharmaceutical company’s stock worth $30,195,000 after buying an additional 139,934 shares during the last quarter. Institutional investors own 77.33% of the company’s stock.
In related news, insider Rajiv Patni sold 1,252 shares of the business’s stock in a transaction that occurred on Wednesday, March 21st. The stock was sold at an average price of $25.94, for a total value of $32,476.88. Following the completion of the sale, the insider now directly owns 21,515 shares in the company, valued at approximately $558,099.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Gregory T. Went sold 4,541 shares of the business’s stock in a transaction that occurred on Wednesday, March 21st. The stock was sold at an average price of $25.75, for a total value of $116,930.75. Following the completion of the sale, the chief executive officer now owns 182,610 shares of the company’s stock, valued at $4,702,207.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,360 shares of company stock valued at $164,138. Corporate insiders own 29.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Q1 2018 EPS Estimates for Adamas Pharmaceuticals Decreased by Analyst (ADMS)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://ledgergazette.com/2018/04/18/q1-2018-eps-estimates-for-adamas-pharmaceuticals-decreased-by-analyst-adms.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.